Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis

* Documented HIV positive status

* Clinical examination of oropharynx is consistent with diagnosis of oral Candidiasis (such as creamy, white, curdlike patches or erythematous lesions on mucosal surfaces)

* Findings on direct microscopic examination (Gram Stain or potassium hydroxide smear) consistent with Candida species or positive fungal culture for Candida species, with culture obtained in the 2 days preceding initiation of therapy with the study drug

* Male or female patients ≥ 18 years

* For women of childbearing potential: negative blood or urine pregnancy test and agreement to use adequate contraception (investigator's discretion) while on study drug

* Mental status allows comprehension of instructions for troche administration

* Written informed consent

* Sings of symptoms suggestive of esophageal Candidiasis (such as dysphagia or odynophagia) unless the results of an endoscopic evaluation of the esophagus are negative

* Presence of perioral lesions only

* Use of other antifungal agents within 5 days of enrollment to the study

* Pregnant or lactating women

* History of hypersensitivity to imidazole or azole compounds

* Patient unwilling or unable to be followed at the study center for the duration of the study (3 weeks)

* Patients has received an investigational drug in the last 30 days

* Treatment with another investigational drug is planned within the next 3 weeks